Xortx Gets Orphan Drug Nod for Polycystic Kidney Disease
Xortx Therapeutics has received Orphan Drug designation for its Xorlo (oxypurinol) drug to treat autosomal dominant polycystic kidney disease, the most common form of polycystic kidney disease.
Xorlo inhibits the production of uric acid, a key to reducing injury to the kidney.
The company plans on speaking with the FDA on May 1 about its planned phase 3 clinical program of the drug candidate.
Orphan Drug designation offers incentives for companies such as a possible tax credit of 25 percent of qualified clinical drug testing costs upon drug approval.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX, dedicated to developing medications to improve the quality of life and future health of patients. Founded: 2011. Headquarters: Vancouver, Canada.
April 24, 2023
https://www.fdanews.com/
Xorlo inhibits the production of uric acid, a key to reducing injury to the kidney.
The company plans on speaking with the FDA on May 1 about its planned phase 3 clinical program of the drug candidate.
Orphan Drug designation offers incentives for companies such as a possible tax credit of 25 percent of qualified clinical drug testing costs upon drug approval.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. XORTX, dedicated to developing medications to improve the quality of life and future health of patients. Founded: 2011. Headquarters: Vancouver, Canada.
April 24, 2023
https://www.fdanews.com/
